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PD-1 expression is upregulated on adapted T cells in
experimental autoimmune encephalomyelitis but is not
required to maintain a hyporesponsive state
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T cell adaptation is an important peripheral tolerogenic process which ensures that
the T cell population can respond effectively to pathogens but remains tolerant to self-
antigens. We probed the mechanisms of T cell adaptation using an experimental autoim-
mune encephalomyelitis (EAE) model in which the fate of autopathogenic T cells could be
followed. We demonstrated that immunisation with a high dose of myelin basic protein
(MBP) peptide and complete Freund’s adjuvant failed to effectively initiate EAE, in contrast
to low dose MBP peptide immunisation which readily induced disease. The proportion of
autopathogenic CD4+ T cells in the central nervous system (CNS) of mice immunised with
a high dose of MBP peptide was not significantly different to mice immunised with a low
dose. However, autopathogenic T cells in mice immunised with high dose MBP peptide
had an unresponsive phenotype in ex vivo recall assays. Importantly, whilst expression
of PD-1 was increased on adapted CD4+ T cells within the CNS, loss of PD-1 function
did not prevent the development of the unresponsive state. The lack of a role for PD-1 in
the acquisition of the adapted state stands in striking contrast to the reported functional
importance of PD-1 in T cell unresponsiveness in other disease models.
Keywords: Adaptation  Autoimmunity  Experimental autoimmune encephalomyelitis  PD-1
 T cell
 Additional supporting information may be found online in the Supporting Information sectionat the end of the article.
Introduction
Understanding how the immune system is able to deal with a
diverse range of pathogens yet remain tolerant to self-antigens is
Correspondence: Prof. Richard J. Mellanby
e-mail: Richard.Mellanby@ed.ac.uk
one of the great challenges in cellular immunology [1]. The steady
increase in incidence and prevalence of autoimmune diseases
across the globe over the past decades emphasises the importance
of identifying the mechanisms by which self-tolerance is main-
tained [2, 3]. Central and peripheral tolerogenic mechanisms play
a key role in ensuring that the T cell repertoire is highly diverse
yet is sufficiently well regulated to prevent the development of an
C© 2018 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co.
KGaA, Weinheim.
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autopathogenic T cell response [1, 4–7]. Collectively, these mech-
anisms ensure that the T cell population can respond effectively
to a pathogen challenge but that this response does not result in
over-zealous immune activation which would lead to long term
damage to the host.
The development of an unresponsive state following exposure
to antigen was first termed anergy based on in vitro studies of
murine and human T cell clones [8]. Anergy can be induced
through several approaches, including the presentation of anti-
gen in the absence of co-stimulation from antigen presenting
cells [9, 10] and induction of sustained calcium signalling [11].
Key features of anergy include the failure to produce selective
cytokines, notably interleukin-2 (IL-2), in response to antigen re-
stimulation, the lack of a requirement for antigen to maintain the
anergic state and the ability of IL-2 to reverse anergy [8]. In con-
trast, T cells which develop an unresponsive state post antigen
stimulation in vivo appear to have a different phenotype from in
vitro anergic cells [12]. Typically, T cells which are hyporesponsive
to TCR re-stimulation following primary antigen exposure in vivo
down-regulate the production of all cytokines and require anti-
gen persistence to maintain the unresponsive state, which cannot
be reversed by addition of IL-2. A variety of in vivo manipula-
tions have been applied to induce a hyporesponsive state in T cells
which has been termed adaptive tolerance [8, 12–19].
The regulatory processes or molecules involved in the develop-
ment and maintenance of an adapted state in T cells in the context
of autoantigens are poorly understood. Recently, the co-inhibitory
receptor programmed cell death protein 1 (PD-1) has been impli-
cated in the development of T cell tolerance following administra-
tion of soluble peptide, also termed peptide immunotherapy [20].
PD-1 is upregulated on CD4+ T cells following activation and
thereby restrains the primary immune response [21]. Mice that
lack PD-1 develop spontaneous autoimmune pathology [22] and
signalling through PD-1 after T cell receptor (TCR) stimulation
inhibits proliferation of T cells and reduces the production of effec-
tor cytokines [23]. The discovery of PD-1/PD-L1 interaction as a
target for checkpoint inhibition has led to several successful clin-
ical trials and the approval of PD-1 inhibitors as treatment for
a number of cancer types [24–26]. However, it remains unclear
whether PD-1 plays a role in the development of T cell adaptation
in vivo following exposure to high concentrations of autoantigen
under pro-inflammatory conditions.
In this study we probed the mechanisms and consequences of
T cell adaptation in experimental autoimmune encephalomyelitis
(EAE), a widely used model of multiple sclerosis. In this model,
CD4+ T cells are activated by immunisation with CNS antigens in
peripheral lymph nodes or ex vivo pre-activated cells are injected
into the bloodstream, and effector T cells consequently make
their way into the CNS where they cause inflammation upon re-
encounter with their cognate antigen. We were particularly inter-
ested to establish whether adapted T cells could traffic to a site
of autoantigen presentation and to define whether increased PD-1
expression played a critical role in the development of the adapted
state.
Results
High dose of agonist stimulation in vitro results in
CD4+ T cell adaptation
The Tg4 transgenic mouse provides a source of na¨ıve T cells
expressing a TCR with a moderate affinity for the Ac1-9-I-Au
complex [27]. Substitution of a tyrosine for the native lysine at
position 4 increases the MHC binding affinity by approximately
1 million fold, creating a superagonist ligand (4Tyr) for Tg4 cells
in vitro [28]. Initially, we examined how varying the concentra-
tion of MBP Ac1-9(4Tyr) peptide influenced the proliferation of
Tg4 T cells in vitro. As expected, increasing the dose of MBP Ac1-
9(4Tyr) resulted in an increase in proliferation and production of
effector cytokines (Fig. 1A). In the next experiment, we examined
how the Tg4 T cell lines (TCL) proliferated in a recall assay after
initial stimulation with MBP Ac1-9(4Tyr) peptide. In order to do
this we generated Tg4 TCL by initially stimulating Tg4 splenocytes
with either 1μM, 0.1μMor 0.01μMMBPAc1-9(4Tyr). After 48 h,
live cells were isolated and the T cell population was expanded in
media enriched with T cell growth factors for a further 4 days prior
to isolation of CD4+ Tg4 TCL by FACS (Supporting Information
Fig. 1). In contrast to the findings during the primary stimulation,
we found that Tg4 TCL generated through initial stimulation with
1 μM MBP Ac1-9(4Tyr) subsequently proliferated less, and pro-
duced lower amounts of pro-inflammatory cytokines, than cells
stimulated with initially lower doses of antigen when co-cultured
with irradiated AMK35 splenocytes which constitutively express
a MBP epitope in MHC class II molecules [29] (Fig. 1B). From
this we concluded that initial stimulation with high dose peptide
resulted in the generation of a population of hyporesponsive T cells
which proliferated less and produced a reduced amount of effector
cytokines when stimulated with antigen on a second occasion.
In order to examine whether the adapted state could be over-
come through signalling downstream of the TCR, the three Tg4
TCL were stimulated with phorbol myristate acetate (PMA) and
ionomycin. As shown in Fig. 1C, all TCL produced similar concen-
trations of IL-2 and IFN-γ in response to PMA and ionomycin. This
demonstrated that the adapted state was maintained through dif-
ferential signalling between the TCR and I-Au-MBP complex and
upstream T cell activation pathways, since re-stimulation with
PMA and ionomycin resulted in equivalent proliferation and effec-
tor cytokine production in the three Tg4 TCL.
Immunisation with high dose of MBP does not result
in deletion of MBP-responsive CD4+ T cells
The above experiments examined the effects of varying antigen
concentration on future T cell phenotypes in vitro. Next, we
wanted to examine whether T cells were adapted in vivo following
high dose immunisation with MBP Ac1-9(4Tyr). Host C57BL/6 x
B10.PL mice were seeded with Tg4.CD45.1 CD4+ T cells and 24 h
C© 2018 The Authors. European Journal of Immunology published by
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Figure 1. High dose of agonist stimulation in vitro results in CD4+ T cell
adaptation. (A) Splenocytes isolated from naı¨ve Tg4 transgenic mice
were cultured in the presence of 1 μM (dark circle), 0.1 μM (triangle) and
0.01 μM (open circle) 4Tyr MBP, and IL-2 and GM-CSF production was
analysed by ELISA 48 and 72 h later, respectively. (B) Proliferation (as
measured by thymidine incorporation) and IL-2, IFNγ and GM-CSF pro-
duction (analysed by ELISA) of Tg4 TCL cells generated in the presence
of 1 μg/mL (dark circle) 0.1 μM (triangle) or 0.01 μM (open circle) of MBP
Ac1-9(4Tyr) following re-stimulation with varying numbers of spleno-
cytes from AMK35 mice expressing MBP. (C) IL-2 and IFN-γ production
from Tg4 TCL cells generated in the presence of 1 μg/mL (dark circle)
0.1 μM (triangle) or 0.01 μM (open circle) of MBP Ac1-9(4Tyr), following
re-stimulation with ionomycin and PMA at indicated concentrations.
Data are shown as mean±SEM from a single experiment, representa-
tive of three independent experiments. Each experiment contained a
minimum of three pooled Tg4 spleens (t-test, **p < 0.01, ***p < 0.001).
Figure 2. Immunisation with high dose of agonist in-vivo does not
result in deletion of agonist-responsive CD4+ T cells. C57BL/6xB10.PL
mice were seeded with CD4+CD45.1+ Tg4 cells and immunised the fol-
lowing daywith either 10 or 100 μgMBPAc1-9(4Tyr) and CFA.Micewere
sacrificed 6 days following immunisation. Total numbers of spleno-
cytes, as well as numbers and frequencies of CD4+CD45.1+ Tg4 cells in
the spleen at day 6 in mice immunised with either 10 μg (open circles)
or 100 μg (dark circles) 4Tyr MBP as assessed by manual counting with
a haemocytometer and by flow cytometry. Data are shown as scatter
plots with the mean indicated by horizontal bar, from a single exper-
iment representative of two independent experiments with n = 6–8
mice per experimental group (Mann–Whitney U test; NS, no significant
difference).
later were immunised with either 10 μg or 100 μg of MBP Ac1-
9(4Tyr) in Complete Freund’s Adjuvant (CFA). Six days later, the
mice were sacrificed and FACS analysis was performed on single
cell preparations of the spleen (Supporting Information Fig. 2).
The total number of cells, number of Tg4 CD4+ T cells and the
proportion of Tg4 cells in the CD4+ population were not signifi-
cantly different between the two groups of mice (Fig. 2). These
observations demonstrate that high dose immunisation of MBP in
vivo does not lead to the deletion of MBP responsive CD4+ T cells.
Immunisation with high dose of MBP results in
attenuation of EAE
In order to examine whether high dose immunisation with MBP
could attenuate EAE, we immunised mice with either 10 μg or
100 μg of MBP Ac1-9(4Tyr) and then monitored the mice daily
for motor neurological function. Mice immunised with 10 μg MBP
Ac1-9(4Tyr) developed a synchronous course of EAE whereas
mice immunised with 100 μg MBP Ac1-9(4Tyr) had a signifi-
cantly lower incidence and severity of EAE (Fig. 3A). Eighteen
of 22 mice developed EAE following immunisation with 10 μg
MBP Ac1-9(4Tyr) compared to only 5 of 22 mice immunised with
100 μg MBP Ac1-9(4Tyr).
To examine whether this was due to a failure of the Tg4 cells
to access the CNS following immunisation with 100 μg MBP
Ac1-9(4Tyr), mice in a subsequent experiment were sacrificed
12 days after immunisation. The total number of cells and num-
ber of Tg4.CD45.1 CD4+ cells were not significantly different in
the spleen or CNS between the 2 groups (Fig. 3B). The propor-
tion of Tg4 cells of all CD4+ T cells was significantly higher in
both the spleen and CNS in mice immunised with 100 μg MBP
Ac1-9(4Tyr) (Fig. 3B, Supporting Information Fig. 3). Following
overnight re-stimulation with 20 μM MBP Ac1-9(4Lys), the pro-
duction of cytokines by Tg4 cells was assessed in both groups.
C© 2018 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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In mice immunised with 100 μg MBP Ac1-9(4Tyr), the propor-
tion of Tg4 cells from both the spleen and CNS expressing pro-
inflammatory cytokines was significantly reduced (Fig. 3C).
Adapted T cells do not have a regulatory phenotype
A potential explanation for the adapted T cell phenotype is that
high dose immunisation results in the development of T cells with
a regulatory T cell phenotype. In order to examine this possibil-
ity, we assessed Foxp3 expression, which is a transcription factor
widely used to identify regulatory T cells [7], within Tg4 cells
at peak of disease. We found no differences in Foxp3 expression
in the transferred Tg4 cells from mice immunised with 10 μg or
100 μg of MBP Ac1-9(4Tyr) (Fig. 4A). Furthermore, we found no
evidence that in vivo adapted cells produced more IL-10 following
overnight re-stimulation with 20 μM MBP Ac1-9(4Lys) (Fig. 4B).
Adapted T cells express higher levels of PD-1
In order to probe the mechanism of the adapted state, the cell
surface expression of a panel of co-stimulatory and co-inhibitory
molecules were examined on our three Tg4 TCL by flow cytometry.
As shown in Fig. 5A, in vitro adapted T cells did not express altered
levels of CD3 or TCRβ but did express higher levels of PD-1, a
molecule which is known to have an important inhibitory effect
on T cell activation. The expression of PD-1 was then examined
on Tg4 cells in mice immunised with either 10 μg or 100 μg MBP
Ac1-9(4Tyr). The expression of PD-1 was significantly increased
on Tg4 cells recovered from the CNS, but not the spleen of mice
immunised with 100 μg MBP Ac-1-9(4Tyr) at the peak of disease
(Fig. 5B).
PD-1 deficient T cells can still acquire an adapted
phenotype in vitro and in vivo
Given the clear association between T cells which had an impaired
ability to respond to MBP agonist on re-stimulation and increased

Figure 3. Adapted T cells can access CNS but have significantly
reduced pathogenic potential. C57BL/6xB10.PL hosts were seeded with
Tg4CD4+CD45.1+ T cells and 1 day later were immunised with CFA
and 10 μg 4Tyr MBP or 100 μg MBP Ac1-9(4Tyr). (A) The disease course
of mice immunised with either 10 μg MBP Ac1-9(4Tyr) (open circles,
n = 22) or 100 μg MBP Ac1-9(4Tyr) (dark circles, n = 22) (Fisher’s exact
test, p<0.0005). Differences in peak disease severity between the groups
was analysed with Mann–Whitney U test, p < 0.0001. Data shown as
mean±SEM, pooled from three independent experiments. (B) Micewere
sacrificed 12 days following immunisation. Total numbers of cells, as
well as numbers of Tg4 cells and frequencies of CD4+CD45.1+ cells
which were Tg4, i.e. donor cells, are shown for the spleen and CNS.
(C) Frequencies of splenic or CNS-infiltrating Tg4 cells producing GM-
CSF, IFN-γ and TNF-α following overnight stimulation with 20 μM MBP
Ac1-9(4Lys). Data are shown as scatter plots with themean indicated by
horizontal bar, froma single experiment representative of two indepen-
dent experiments with n = 6–8 per experimental group (Mann–Whitney
U test; NS, no significant difference).
C© 2018 The Authors. European Journal of Immunology published by
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Figure 4. Adapted T cells do not have a regulatory T cell phenotype (A)
C57BL/6xB10.PL hosts were seeded with Tg4 CD4+CD45.1+ T cells and
1 day later immunised with CFA and 10 μg MBP Ac1-9(4Tyr) or 100 μg
MBP Ac1-9(4Tyr). Mice were sacrificed 12 days following immunisa-
tion. Proportions of Fopx3+ of CD4+CD45.1+ (Donor) and CD4+CD45.1−
(Host) cells in the mononuclear cell preparations from the CNS of mice
immunised with 10 μg MBP Ac1-9(4Tyr) (open circles) or 100 μg MBP
Ac1-9(4Tyr) (dark circles) were determined by flow cytometry. Data
are representative of two independent experiments containing 4–6
mice per group (Mann–Whitney U test; NS, no significant difference).
(B) Splenocytes of mice 12 days post immunisation with 10 μg MBP
Ac1-9(4Tyr) (open circles) or 100 μg MBP Ac1-9(4Tyr) (dark circles) were
re-stimulated with 20 μMMBP Ac1-9(4Lys) overnight and IL-10 concen-
trations were measured in the supernatants. Data are shown as scatter
plots with the mean indicated by horizontal bar, representative of two
independent experiments containing 4–6 mice per experimental group
(Mann–Whitney U test; NS, no significant difference).
expression of PD-1, we next wanted to examine whether increased
PD-1 expression was required to maintain the adapted T cell state.
T cell lines were generated from Tg4 WT and Tg4.PD-1−/− [20]
splenocytes which were stimulated with either 1, 0.1 or 0.01 μM
of MBP Ac1-9(4Tyr). The TCL generated from both Tg4 WT and
Tg4.PD-1−/− splenocytes initially treated with the high dose of
MBP Ac1-9(4Tyr) displayed the typical adapted phenotype with
reduced IL-2 production (Fig. 5C). A second, independent exper-
iment found the same adapted phenotype in both Tg4 WT and
Tg4.PD-1−/− TCL when using thymidine incorporation rather than
IL-2 as a readout of proliferation (Fig. 5D). To explore whether the
loss of PD-1 altered the ability of Tg4 cells to be adapted in vivo,
we seeded host mice with Tg4.PD-1−/− CD4+ cells and immu-
nised the mice with either 10 μg or 100 μg MBP Ac1-9(4Tyr).
Mice immunised with high dose MBP Ac1-9(4Tyr) developed a
significantly attenuated course of EAE which resembled that of
mice seeded with Tg4 WT CD4+ cells under the same experimen-
tal conditions (Fig. 5E, Fig. 3A). These experiments demonstrated
that loss of PD-1 expression did not limit the ability of Tg4 CD4+
T cells to be adapted in vitro or in vivo.
Discussion
The induction of antigen-specific tolerance is one of the fun-
damental mechanisms of peripheral tolerance. The utilisation
and/or mimicking of in vivo tolerance mechanisms is a promising
strategy to achieve antigen-specific, targeted immunosuppression
for immune-mediated pathologies such as autoimmune diseases,
allergy, and allograft rejection [30]. Whilst deletion of autoreac-
tive T cells is a knownmechanism of peripheral tolerance [31], our
study demonstrates that the administration of high dose agonist
in conjunction with adjuvant does not invariably lead to whole-
sale loss of T cells which can respond to this antigen. Instead,
we observed an expansion of T cells which had a greatly reduced
ability to proliferate and produce pro-inflammatory cytokines.
Tolerance against autoantigens is most commonly observed
upon administration or presentation in the absence of pro-
inflammatory stimuli. However, high doses of antigen or chronic
exposure to antigen, best studied in the context of viral infection
and cancer, can result in a hyporesponsive T cell state even in
the presence of immune stimuli that support immune responses
at other levels of antigen exposure. In the context of autoimmune
disease, molecular mimicry is one of the hypothesisedmechanisms
by which autopathogenic immune responses can be initiated [6].
It involves an initial peripheral infection to activate T cells which
also recognise self-antigen due to TCR degeneracy; these then
go on to cause an autoimmune response upon encounter of this
self-antigen if not tolerised. One way of achieving tolerance in
this setting would be a reduction of T cell trafficking to the site
of self-antigen, in the case of this experimental set-up, the CNS.
However, we found that the hyporesponsive, adapted T cells could
still traffic to the CNS. Indeed, the Tg4 CD4+ T cells capable of
responding to MBP were present in similar numbers in the CNS of
asymptomatic mice immunised with high dose MBP as mice with
EAE which had been administered a lower dose of MBP. In both
groups, there were significant numbers of mononuclear cells in the
CNS which were not Tg4 cells. Whilst the Tg4 CD4+ T cells are
essential for initiating disease in B10.PL × C57BL/6 mice immu-
nised with low dose MBP [32], non Tg4 immune cells are likely
to play a role in propagating CNS pathology. This indicates that
the CNS was exposed to a similar number of MBP responsive cells
but the process of adaptation had rendered them unable to initiate
autoimmune pathology. This process may be important in protect-
ing the host from the development of an autopathogenic immune
response when the immune system is exposed to autoantigens in
an inflammatory milieu through trauma or infection. Epidemio-
logical data supports this hypothesis since a traumatic event does
not invariably precede the development of autoimmunity [33].
Whether our observations can be readily extrapolated to other
C© 2018 The Authors. European Journal of Immunology published by
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antigens beyond modified MBP and ultimately, to polyclonal T cell
responses, remains to be clarified.
In recent years, it has been established that PD-1 is an impor-
tant molecule in restraining T cell effector function following ini-
tial activation. The first evidence for the role of PD-1 inmodulating
T cell activation came from PD-1 deficient mice which developed
multi-organ autoimmunity [34]. Interaction of PD-1with its ligand
PD-L1 or PD-L2 and downstream signalling results in the atten-
uation of the functional and proliferative capabilities of T cells,
e.g. via repression of TCR signalling [35], induction of inhibitory
genes [36], and reduction of T cell motility [37]. The therapeutic
blockade of PD-1 has been a major breakthrough in the treatment
of several types of cancer, facilitating a more effective cytotoxic
T cell response [22, 25, 38]. On the other hand, enhancement
of the PD-1/PDL-1 axis is considered a promising target in the
context of autoimmune disease. A recent study from our group
demonstrated that the effectiveness of peptide immunotherapy is
reliant on persistent expression of PD-1 on tolerised T cells [20].
Data from the current study show that upregulated expression of
PD-1 is maintained on hyporesponsive T cells which have been
generated either in vitro or in vivo. However, using T cells which
were deficient in PD-1, we were able to demonstrate that PD-
1 expression is not required to develop a hyporesponsive state
when high levels of autoantigen agonists are delivered alongside
a powerful pro-inflammatory adjuvant. Why PD-1 expression is
indispensable for the maintenance of a hyporesponsive state in
Tg4 CD4+ cells tolerised by soluble peptide, but not in hypore-
sponsive T cells generated post peptide administration with CFA,
remains unclear but may relate to the induction of an alternative

Figure 5. PD-1 expression is increased on adapted T cells generated in
vitro and in vivo but is not required to maintain adapted state (A) Cell
surface expression of CD3, TCRβ and PD-1 and isotype control stain-
ing (grey shaded area) on Tg4 TCL cells generated in the presence of
1 μg/mL (solid line) or 0.01 μg/mL (dashed line) of MBP Ac1-9(4Tyr). Cells
were analysed by flow cytometry and gated on CD4+ live cells. Data are
representative of four independent experiments, with each experiment
containing aminimumof 3 pooled Tg4 spleens per experimental group.
(B) C57BL/6xB10.PL hostswere seededwith Tg4CD4+CD45.1+ T cells and
1 day later were immunised with CFA and 10 μg MBP Ac1-9(4Tyr) (open
circle) or 100μg MBP Ac1-9(4Tyr) (dark circle). Mice were sacrificed 12
days following immunisation. PD-1 expression on CD4+CD45.1+ T cells
from the spleen and CNS was analysed as mean fluorescence inten-
sity (MFI). Data are shown as scatter plots with the mean indicated by
horizontal bar, representative of two independent experiments con-
taining 6–8 mice per experimental group (Mann–Whitney U test; NS, no
significant difference). (C) IL-2 production by Tg4 (left panel) and PD-
1−/− Tg4 (right panel) TCL cells generated in the presence of 1 μg/mL
(dark circle) or 0.01 μM (open circle) of MBP Ac1-9(4Tyr) following re-
stimulation with varying numbers of splenocytes from AMK35 mice
expressingMBP (t-test, *p< 0.05, **p< 0.01, ***p< 0.001). (D) Proliferation
of Tg4 (left panel) and PD-1−/− Tg4 (right panel) TCL cells generated in
the presence of 1 μg/mL (dark circle) or 0.01μM (open circle) of MBP Ac1-
9(4Tyr) following re-stimulation with varying numbers of splenocytes
from AMK35 mice expressing MBP, as measured by thymidine incorpo-
ration (t-test, *p<0.05, **p < 0.01, ***p < 0.001). (E) C57BL/6xB10.PL mice
were seeded with PD-1−/− Tg4 CD4+ T cells and 1 day later immunised
with either 10 μg (open circles) or 100 μg (dark circles) MBP Ac1-9(4Tyr)
in CFA and disease course was monitored (Fisher’s exact test, p < 0.01).
Differences in peak disease severity between the groups were analysed
with Mann–Whitney U test, p < 0.0005. Data are pooled from two inde-
pendent experiments with a total of 14 mice per experimental group.
C© 2018 The Authors. European Journal of Immunology published by
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inhibitory pathway driven by the adjuvant [39]. A better under-
standing of the distinct hyporesponsive T cell states, their devel-
opment, maintenance, and relevance in immune homeostasis and
disease is required in order to optimise therapeutic approaches
targeting T cell responsiveness [40].
A hallmark of regulatory T cells is unresponsiveness to anti-
gen stimulation, so a plausible explanation for the persistence of
hyporesponsive cells following high dose immunisation with MBP
is the development of a regulatory T cell phenotype. However,
we found no evidence that adapted T cells – although unrespon-
sive to secondary antigen stimulation – acquired the expression of
transcription factor Foxp3, a marker for thymus-derived as well
as peripherally-induced regulatory T cells [7, 41, 42]. Likewise,
no increase in production of IL-10, a potent anti-inflammatory
cytokine produced by Foxp3+ as well as Foxp3− T cells with reg-
ulatory function was observed in adapted T cells [7]. A limita-
tion of our experimental approach was the failure to assess IL-10
production from Tg4 using intracellular cytokine approach as we
employed in the assessment of pro-inflammatory cytokine produc-
tion. The finding that adapted T cells in our experimental system
did not acquire a regulatory T cell phenotype is consistent with
other studies which have investigated the in vivo development of
a hyporesponsive state in T cells post antigen exposure [43].
In conclusion, we show that a high dose of self-antigen ago-
nist in the presence of adjuvant results in T cell tolerance, which
follows initial T cell expansion and does not involve clonal dele-
tion, autoantigen ignorance, or acquisition of a regulatory phe-
notype. Most strikingly, this in vivo adapted T cell phenotype
is independent of PD-1, which stands in contrast with several
other described forms of T cell unresponsiveness, including in
the context of chronic viral infections and cancer. These insights
into adapted T cell tolerance are important in the development of
antigen-specific therapy for autoimmune diseases.
Materials and methods
Mice, antigens and tissue culture medium
B10.PL x C56BL/6, AMK35,Tg4.CD45.1 and Tg4.CD90.1 mice
were bred under specific pathogen-free conditions at the Uni-
versity of Edinburgh. All experiments had local ethical approval
and were performed in accordance with UK legislation. Tg4 mice
express a transgenic T cell receptor (TCR) recognizing the Ac1-
9 peptide of MBP in association with I-Au [27]. AMK35 mice
express the MBP Ac1-9 peptide covalently bound to all I-AU major
histocompatibility molecule (MHC) class II molecules [29]. The
MBP Ac1-9(4Tyr) analog peptide was obtained from Cambridge
Research Biochemicals (Cleveland, UK). Tissue culture medium
(RPMI 1640 medium) was supplemented with 2 mM L-glutamine,
100 U/ml penicillin, 100 μg/ml streptomycin, and 5 × 10–5 M 2-
ME (all from Invitrogen Life Technologies, Paisley, UK) and 10%
FCS (Sigma-Aldrich, Dorset, UK).
Induction of active EAE
B10.PL x C57BL/6 (CD45.2) mice received 1 × 106 Tg4.CD45.1
CD4+ T cells. One day later (day 0), mice received 10μg or 100μg
of the MBP Ac1-9(4Tyr) peptide emulsified in CFA containing
50 μg of heat-killed Mycobacterium tuberculosis H37Ra (Sigma-
Aldrich, Dorset, UK) at a total final volume of 50 μl injected s.c.
into each hind leg. On the day of immunization and 48 hrs later,
each mouse also received 200 ng of pertussis toxin (Health Protec-
tion Agency, Dorset, U.K.) in 0.5 mL PBS via i.p. injection. Clinical
signs of EAE were assessed daily with the following scoring sys-
tem: 0, no signs; 1, flaccid tail; 2, impaired righting reflex and/or
gait; 3, partial hind limb paralysis; 4, total hind limb paralysis; 5,
hind limb paralysis with partial front limb paralysis; 6, moribund
or dead. In some experiments, the mice were sacrificed pre dis-
ease development on day 6 or at peak of disease at day 12 post
immunisation.
Generation of Tg4 T cell lines, primary activation
assays and recall assays
To study the primary activation of Tg4 CD4+ T cells, spleens from
Tg4 mice were harvested, single cell preparation was performed
and red blood cells were lysed using an ammonium chloride buffer
(Sigma Aldrich, Dorset, UK). Varying numbers (as stated) of Tg4
splenocytes cells per well (flat bottomed, 96 well plates) were cul-
tured with stated concentration of MBP Ac1-9(4Tyr). After 48 h,
cell proliferation was assessed by the addition of [3H]thymidine
(PerkinElmer, Cambridge, UK) at 0.5μCi/well for the last 18 h
of culture. [3H]Thymidine incorporation was measured using a
scintillation β-counter (Wallac, Milton Keynes, UK). The results
are expressed as mean counts per minute (c.p.m.) ± standard
error of the mean (SEM). Tg4 CD4+ T cell production of cytokines
(IL-2 and IFN-γ) was assessed in culture supernatants by ELISA
using paired monoclonal antibodies and recombinant cytokine
standards purchased from BD Biosciences (New Jersey, USA). GM-
CSF was detected using Ready-SET-Go ELISA kits (eBioscience,
San Diego, USA). IL-2 was measured in supernatants after 48 h of
culture and IFN-γ and GM-CSF was measured after 72 h of culture.
Tg4 CD4+ T cell lines were generated by culturing Tg4 spleno-
cytes with the stated concentration of MBP Ac1-9(4Tyr) for 48 h.
Cells were plated out in 24-well plates at 3 × 106/mL with 1.5 mL
in each well. T cell blasts were then isolated using Ficoll-Paque
1.077 (GE Healthcare Life Sciences, Buckinghamshire, UK). The
isolated cells were expanded for a further 4 days at 2 × 106/mL
in tissue culture media supplemented with 2.5% concanavalin A-
activated rat spleen supernatant as a source of T cell growth fac-
tors in 24 well plates. To examine response to recall stimulation
to MBP, 2 × 104/ well Tg4 CD4+ TCL were co-cultured in 96 well
plates with the stated concentration of irradiated (30 Gy) AMK35
splenocytes for 72 h. Response to a non TCR activation stimu-
lus was examined by culturing 1 × 105/ well Tg4 TCL with the
stated amount of ionomycin and PMA. Proliferation and cytokine
production were assessed as described above.
C© 2018 The Authors. European Journal of Immunology published by
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Flow cytometry analysis
Cells were re-suspended in FACS buffer (PBS, 2% fetal calf serum,
0.01% sodium azide) (Sigma Aldrich, Dorset, U.K.). Mice with EAE
were sacrificed by CO2 asphyxiation, perfused with cold PBS and
mononuclear cells were prepared from the brain and spinal cord as
described previously [44]. Spinal cords were removed by intrathe-
cal hydrostatic pressure. Brain and spinal cords were cut into small
pieces and digested with 2.5 mg/mL collagenase (Worthington
Biochemical) and 1 mg/mL deoxyribonuclease (Sigma-Aldrich)
for 25minutes at 37°C followed bymechanical disaggregation. Sin-
gle cell suspensions were washed once in tissue culture medium.
Mononuclear cells from the CNS were prepared from the interface
of a 30:70% discontinuous Percoll gradient after centrifugation for
20 minutes at 850 × g. Cells were re-suspended in 1mL tissue cul-
ture medium and cell numbers were manually determined using
a cell counting chamber, with the addition of 0.4% Trypan Blue
for exclusion of dead cells. Analysis of CNS mononuclear pheno-
type and function was performed by flow cytometry as described
in relevant methods and results sections, and adhered to guide-
lines as described in Cossarizza et al. [45]. The number of Tg4
donor cells was calculated based on the percentage of CD45.1+
cells of live singlet cells as determined by flow cytometric analysis.
Fc receptors were blocked with supernatant from the hybridoma
2.4G2. All antibodies used were from eBioscience, Hatfield, UK,
except where stated; LIVE/DEAD fixable cell stain (Life Technolo-
gies), anti-CD4-PerCP, anti-CD4-AF700 (BD Pharmingen, Oxford,
UK), anti-CD90.1-APC, anti-CD45.1-FITC, anti-TNFα-efluor450,
anti-IFNγ-FITC, anti-GM-CSF-PE and anti-Foxp3-PE (AbD Serotec,
Kidlington, UK). For intracellular staining in response to peptide,
cells were re-suspended at 1 × 107/mL in the presence or absence
of 20 μM 4Lys MBP. After overnight culture, 1 μl/mL of brefeldin
A (e-bioscience, Hatfield, UK, 1000x stock) was added for the
last four hours of culture. Cells were surface stained prior to pro-
cessing for intracellular staining using appropriate buffers accord-
ing to manufacturer’s instructions (eBioscience for transcription
factor staining or Becton Dickinson for cytokine staining). FACS
data were collected using LSR Fortessa (BD Biosciences, New
Jersey, USA) and analyzed using FlowJo software (Tree Star,
Olten, Switzerland). For FACS analysis of CNS mononuclear cells,
mice with EAE were sacrificed by CO2 asphyxiation, perfused
with cold PBS and mononuclear cells were prepared from brain
and spinal cord as described previously [44]. IL-10 was mea-
sured in supernatants of splenocytes stimulated overnight with
MBP using a IL-10 Ready-SET-Go ELISA (eBioscience, San Diego,
USA).
Statistical analysis
Statistical analysis of results was performed using the Mann–
Whitney U test, the two tailed Student’s t-test and Fischer’s exact
test as appropriate. Cytokine concentrations are presented asmean
concentration ± SEM. Significance was set at p < 0.05.
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